Who Paid My Doc Search
Menu
Organisation paid for research Program year 2021 Source: CMS Open Payments

Crisor LLC

Neither a doctor nor a teaching hospital

Research payments

$2,888,770

178 payments

Through program year 2021, Crisor LLC is reported as receiving $2,888,770 in research payments, across 178 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $69,276 12
2020 Research $899,739 77
2019 Research $1,919,755 89

Breakdown

Who paid Research payments · program years 2019–2021
  1. Amphastar Pharmaceuticals, Inc. $954,542 3 payments
  2. Cipla USA Inc. $454,630 10 payments
  3. AstraZeneca Pharmaceuticals LP $323,759 25 payments
  4. AstraZeneca AB $321,053 4 payments
  5. Pfizer Inc. $305,093 44 payments
  6. Sanofi US Services Inc. $211,400 39 payments
  7. Genzyme Corporation $149,309 13 payments
  8. GlaxoSmithKline, LLC. $60,060 22 payments
  9. LEO Pharma AS $48,856 7 payments
  10. Novartis Pharmaceuticals Corporation $39,609 3 payments
Studies the money was for Research payments · program years 2019–2021
  1. Phamacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients $488,829 2 payments
  2. Pharmacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients $465,713 1 payment
  3. U-Fs-Mu-As3120 $454,630 10 payments
  4. A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compared to placebo, in Asthmatics symptomatic on low dose ICS $321,053 4 payments
  5. Jak1 Dupilumab Comparator Study $218,322 22 payments
  6. A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) $123,413 11 payments
  7. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $96,624 4 payments
  8. An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $86,420 16 payments
  9. A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $76,187 8 payments
  10. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $68,496 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record